Open AccessTopical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases
Author(s) -
Lupe G. Salazar,
Hailing Lu,
Jessica Reichow,
Jennifer S. Childs,
Andrew L. Coveler,
Doreen M. Higgins,
James Waisman,
Kimberly H. Allison,
Yushe Dang,
Mary L. Disis
Publication year - 2017
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2016.6007
Subject(s) - medicine , imiquimod , paclitaxel , oncology , dermatology , nab paclitaxel , breast cancer , cancer
Salvage chemotherapy for recurrent chest wall lesions in breast cancer results in response rates of 20% to 30%. Preclinical studies showed significant disease regression could be induced in murine chest wall mammary cancers with a topical toll-like receptor (TLR)-7 agonist, imiquimod.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom